NetworkNewsBreaks – Odyssey Health Inc. (ODYY) A
Post# of 85
(Total Views: 179)
Posted On: 11/03/2022 3:36:45 PM
NetworkNewsBreaks – Odyssey Health Inc. (ODYY) Announces Expansion of Executive Team
Odyssey Health (OTC: ODYY), formerly Odyssey Group International and a medical technology company focused on developing unique, life-saving medical products, is expanding its executive team. The expansion is part of ODYY’s support of and commitment to Odyssey NeuroPharma, the company’s newest entity. Additions to the executive team include Erik Emerson, named chief commercial officer, and Greg Gironda, named chief operating officer. These two together have more than five decades of experience in commercializing innovative pharmaceutical compounds with leading pharmaceutical companies; the pair will work to advance Odyssey’s concussion treatment and Niemann-Pick treatment. According to the announcement, more than 5 million concussions occur every year in the United States alone. With no current treatment approved by the FDA, those dealing with patients represent an underserved population with an urgent need. Odyssey NeuroPharma is planning a phase 2 program designed to evaluate efficacy in support of its extensive safety and animal data. “Odyssey NeuroPharma is dedicated to addressing the unmet medical needs in traumatic brain injury,” said Odyssey Health CEO Michael Redmond in the press release. “Erik and Greg will provide the proven experience and expertise needed to bring this novel treatment through clinical trials and ultimately to commercial launch.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Odyssey Health (OTC: ODYY), formerly Odyssey Group International and a medical technology company focused on developing unique, life-saving medical products, is expanding its executive team. The expansion is part of ODYY’s support of and commitment to Odyssey NeuroPharma, the company’s newest entity. Additions to the executive team include Erik Emerson, named chief commercial officer, and Greg Gironda, named chief operating officer. These two together have more than five decades of experience in commercializing innovative pharmaceutical compounds with leading pharmaceutical companies; the pair will work to advance Odyssey’s concussion treatment and Niemann-Pick treatment. According to the announcement, more than 5 million concussions occur every year in the United States alone. With no current treatment approved by the FDA, those dealing with patients represent an underserved population with an urgent need. Odyssey NeuroPharma is planning a phase 2 program designed to evaluate efficacy in support of its extensive safety and animal data. “Odyssey NeuroPharma is dedicated to addressing the unmet medical needs in traumatic brain injury,” said Odyssey Health CEO Michael Redmond in the press release. “Erik and Greg will provide the proven experience and expertise needed to bring this novel treatment through clinical trials and ultimately to commercial launch.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Odyssey Group Intl Inc (ODYY) Stock Research Links
Scroll down for more posts ▼